Treatment of patients with neuropathy and anti-MAG IgM M-proteins.
Five patients with neuropathy and IgM M-proteins that reacted with myelin-associated glycoprotein (MAG) were treated for 10 to 20 months with cytostatic agents. In 2 patients, a decrease in serum M-protein and in anti-MAG IgM levels coincided with a progressive improvement of neuropathy. No clinical improvement and no decrease of anti-MAG IgM were observed in the other patients. The close relationship between the decrease of anti-MAG M-proteins and clinical improvement in these patients supports the pathogenetic role of the M-protein in the neuropathy.
Nobile-Orazio
E
E
Institute of Clinical Neurology, University of Milan, Italy.
Baldini
L
L
Barbieri
S
S
Marmiroli
P
P
Spagnol
G
G
Francomano
E
E
Scarlato
G
G
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000032:analysis*; D001798:Blood Proteins / Q000032:analysis*; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis*; D007136:Immunoglobulins; D008297:Male; D008875:Middle Aged; D009185:Myelin Proteins / Q000276:immunology*; D018992:Myelin-Associated Glycoprotein; D009468:Neuromuscular Diseases / Q000188:drug therapy* / Q000276:immunology*; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001323:Autoantibodies; D001798:Blood Proteins; D007075:Immunoglobulin M; D007136:Immunoglobulins; C009823:M-proteins (Myeloma); D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D002699:Chlorambucil; D003520:Cyclophosphamide; D011241:Prednisone